Q32 Bio Inc.
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
QTTB | NDAQ
Overview
Corporate Details
- ISIN(s):
- US7469641051 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 830 WINTER STREET, 2451 WALTHAM
- Website:
- https://www.q32bio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Q32 Bio Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative biologic therapeutics designed to restore immune homeostasis. The company develops therapies for severe autoimmune and inflammatory diseases by targeting powerful regulators of the adaptive and innate immune systems to re-balance immunity. Its lead product candidate is bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha (IL-7Rα) monoclonal antibody that re-regulates adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling. Q32 Bio is advancing bempikibart in a Phase 2 clinical program for patients with alopecia areata.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Q32 Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Q32 Bio Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Q32 Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
